<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2016-2-12-16</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-678</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Клиническо е течение и стандарт н а я терапия системной красной волчанки в Российской Федерации</article-title><trans-title-group xml:lang="en"><trans-title>The clinical course and standard therapy of systemic lupus erythematosus in the Russian Federation</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Насонов</surname><given-names>Е. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Nasonov</surname><given-names>E. L.</given-names></name></name-alternatives><email xlink:type="simple">cancelar@irramn.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Соловьев</surname><given-names>С. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Solovyev</surname><given-names>S. K.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лила</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Lila</surname><given-names>A. M.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия; 1115522, Москва, Каширское шоссе 34А&#13;
&#13;
кафедра ревматологии ИПО ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова»,&#13;
Москва, Россия 105043, Москва, ул. Б. Пироговская, 2</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A. Nasonova Research Institute of  heumatology, Moscow, Russia; 34A, Kashirskoe Shosse, Moscow 115522&#13;
&#13;
Department of Rheumatology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia 2, B. Pirogovskaya St., Moscow 105043</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия  1115522, Москва, Каширское шоссе 34А</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A. Nasonova Research Institute of  heumatology, Moscow, Russia  34A, Kashirskoe Shosse, Moscow 115522</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ГБОУ ВПО «Северо-Западный государственный медицинский университет им. И.И. Мечникова», Санкт-Петербург, Россия 191015, Санкт-Петербург, ул. Кирочная, 41</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.I. Mechnikov North-Western State Medical University, Saint Petersburg, Russia 41, Kirochnaya St., Saint Petersburg 11015</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>05</day><month>06</month><year>2016</year></pub-date><volume>10</volume><issue>2</issue><fpage>12</fpage><lpage>16</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Насонов Е.Л., Соловьев С.К., Лила А.М., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Насонов Е.Л., Соловьев С.К., Лила А.М.</copyright-holder><copyright-holder xml:lang="en">Nasonov E.L., Solovyev S.K., Lila A.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/678">https://mrj.ima-press.net/mrj/article/view/678</self-uri><abstract><p>Данные об особенностях клинического течения и лечения такого тяжелого заболевания, как системная красная волчанка (СКВ), в России практически отсутствуют.</p><p>Цель исследования ESSENCE – оценка клинической картины заболевания и его лечения у взрослых пациентов с активной СКВ в городах трех постсоветских государств (Россия, Украина и Казахстан).</p><sec><title>Материал и методы</title><p>Материал и методы. Настоящая публикация касается российских пациентов. Изучены данные (истории болезни) 232 пациентов, которые наблюдались в 6 центрах (Москва, Санкт-Петербург, Воронеж, Екатеринбург, Курск, Ярославль). Оценивали демографические и исходные характеристики пациентов, активность СКВ, лабораторно-инструментальные исследования, лечение и потребляемые ресурсы здравоохранения.</p></sec><sec><title>Результаты</title><p>Результаты. Демографические характеристики пациентов с СКВ были в целом сопоставимы с таковыми в других международных исследованиях. Однако российские пациенты оказались на 4–10 лет моложе, а длительность СКВ у них была на 3–7 лет меньше, у большинства пациентов отмечалось тяжелое течение заболевания. Уровень активности СКВ у пациентов в нашем исследовании был выше. Зафиксированы частые госпитализации и незапланированные визиты к врачу в связи с обострениями. Российские пациенты, обращающиеся за повторной медицинской помощью, имеют выраженные и тяжелые осложнения СКВ. С большой долей вероятности у достаточно большого количества больных заболевание остается недиагностированным или диагноз установлен неправильно. Отмечены недостатки в лечении СКВ: противомалярийные препараты получали менее половины, а глюкокортикоиды – почти 100% больных, нестероидные противовоспалительные препараты назначали редко. Исследование ESSENCE позволяет составить представление о клинической картине СКВ в России. Эти данные могут помочь в планировании ресурсов здравоохранения в нашей стране.</p></sec></abstract><trans-abstract xml:lang="en"><p>Data on the clinical course and treatment of such as the severe disease systemic lupus erythematosus (SLE), are virtually lacking in Russia.</p><sec><title>Objective</title><p>Objective: to evaluate the clinical presentations of the disease and its treatment in adult patients with active SLE in the cities of three post-Soviet countries (Russia, Ukraine, and Kazakhstan) in the ESSENCE study.</p></sec><sec><title>Patients and methods</title><p>Patients and methods. This paper concerns Russian patients. The data of clinical cases of 232 patients who were followed up in 6 centers (Moscow, Saint Petersburg, Voronezh, Yekaterinburg, Kursk, and Yaroslavl) were studied. The demographic and clinical characteristics of the patients, SLE activity, laboratory and instrumental findings, treatment, and consumed healthcare resources were assessed.</p></sec><sec><title>Results</title><p>Results. The demographic characteristics of patients with SLE were generally comparable to those in other international studies. However, the Russian patients were 4–10 years younger and their SLE duration was 3–7 shorter; the majority of patients were noted to have a severe course of the disease. The level of SLE activity was higher in the patients of our study. There were frequent hospitalizations and unplanned visits to a physician because of exacerbations. The Russian patients who had repeatedly sought medical advice had obvious and severe SLE complications. The disease remained with great probability undiagnosed or misdiagnosed in a sufficiently large number of patients. There were pitfalls in the treatment of SLE: less than half of the patients received antimalarial drugs; nearly 100% took glucocorticoids; nonsteroidal anti-inflammatory drugs were used rarely. The ESSENCE study can form a view of the clinical picture of SLE in Russia. These findings may help to plan healthcare resources in our country.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>системная красная волчанка</kwd><kwd>клиническое течение</kwd><kwd>терапия</kwd><kwd>российская популяция больных</kwd></kwd-group><kwd-group xml:lang="en"><kwd>systemic lupus erythematosus</kwd><kwd>clinical course</kwd><kwd>therapy</kwd><kwd>Russian population of patients</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ruiz-Irastorza G, Khamashta MA, Castellino G, et al. Systemic lupus erythematosus. Lancet. 2001 Mar 31; 357(9261):1027-32.</mixed-citation><mixed-citation xml:lang="en">Ruiz-Irastorza G, Khamashta MA, Castellino G, et al. Systemic lupus erythematosus. Lancet. 2001 Mar 31; 357(9261):1027-32.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Doria A, Zen M, Canova M, et al. SLE diagnosis and treatment: when early is early. Autoimmun Rev. 2010 Nov;10(1):55-60. doi: 10.1016/j.autrev. 2010.08.014. Epub 2010 Sep 8.</mixed-citation><mixed-citation xml:lang="en">Doria A, Zen M, Canova M, et al. SLE diagnosis and treatment: when early is early. Autoimmun Rev. 2010 Nov;10(1):55-60. doi: 10.1016/j.autrev. 2010.08.014. Epub 2010 Sep 8.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lopez R, Davidson JE, Beeby MD, et al. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology (Oxford). 2012 Mar;51(3):491-8. doi: 10.1093/rheumatology/ker368. Epub 2011 Nov 21.</mixed-citation><mixed-citation xml:lang="en">Lopez R, Davidson JE, Beeby MD, et al. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology (Oxford). 2012 Mar;51(3):491-8. doi: 10.1093/rheumatology/ker368. Epub 2011 Nov 21.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010 Dec;69(12):2074-82. doi: 10.1136/ard.2010. 130476. Epub 2010 Aug 19.</mixed-citation><mixed-citation xml:lang="en">Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010 Dec;69(12):2074-82. doi: 10.1136/ard.2010. 130476. Epub 2010 Aug 19.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010 Jul;69(7):1269-74. doi: 10.1136/ ard.2009.117200. Epub 2009 Nov 5.</mixed-citation><mixed-citation xml:lang="en">Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010 Jul;69(7):1269-74. doi: 10.1136/ ard.2009.117200. Epub 2009 Nov 5.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Aringer M, Burkhardt H, Burmester GR, et al. Current state of evidence on «off label» therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria, and Switzerland-a consensus report. Lupus. 2012 Apr;21(4):386-401. doi: 10.1177/096120 3311426569. Epub 2011 Nov 9.</mixed-citation><mixed-citation xml:lang="en">Aringer M, Burkhardt H, Burmester GR, et al. Current state of evidence on «off label» therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria, and Switzerland-a consensus report. Lupus. 2012 Apr;21(4):386-401. doi: 10.1177/096120 3311426569. Epub 2011 Nov 9.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bae YI, Yun SJ, Lee JB, et al. A clinical and epidemiological study of lupus erythematosus at a tertiary referral dermatology clinic in Korea. Lupus. 2009 Dec;18(14): 1320-6. doi: 10.1177/0961203309345769. Epub 2009 Nov 2.</mixed-citation><mixed-citation xml:lang="en">Bae YI, Yun SJ, Lee JB, et al. A clinical and epidemiological study of lupus erythematosus at a tertiary referral dermatology clinic in Korea. Lupus. 2009 Dec;18(14): 1320-6. doi: 10.1177/0961203309345769. Epub 2009 Nov 2.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Alonso MD, Llorca J, Martinez-Vazquez F, et al. Systemic lupus erythematosus in northwestern Spain: a 20-year epidemiologic study. Medicine (Baltimore). 2011 Sep;90(5):350-8. doi: 10.1097/MD.0b013e31822edf7f.</mixed-citation><mixed-citation xml:lang="en">Alonso MD, Llorca J, Martinez-Vazquez F, et al. Systemic lupus erythematosus in northwestern Spain: a 20-year epidemiologic study. Medicine (Baltimore). 2011 Sep;90(5):350-8. doi: 10.1097/MD.0b013e31822edf7f.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Feldman CH, Hiraki LT, Liu J, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis Rheum. 2013 Mar;65(3):753-63. doi: 10.1002/art.37795.</mixed-citation><mixed-citation xml:lang="en">Feldman CH, Hiraki LT, Liu J, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis Rheum. 2013 Mar;65(3):753-63. doi: 10.1002/art.37795.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Flower C, Hennis AJ, Hambleton IR, et al. Barbados National Lupus Registry Group. Systemic lupus erythematosus in an African Caribbean population: incidence, clinical manifestations, and survival in the Barbados National Lupus Registry. Arthritis Care Res (Hoboken). 2012 Aug;64(8):1151-8. doi: 10.1002/acr.21656 .</mixed-citation><mixed-citation xml:lang="en">Flower C, Hennis AJ, Hambleton IR, et al. Barbados National Lupus Registry Group. Systemic lupus erythematosus in an African Caribbean population: incidence, clinical manifestations, and survival in the Barbados National Lupus Registry. Arthritis Care Res (Hoboken). 2012 Aug;64(8):1151-8. doi: 10.1002/acr.21656 .</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Doria A, Amoura Z, Cervera R, et al. Annual direct medical cost of active systemic lupus erythematosus in five European countries. Ann Rheum Dis. 2014 Jan;73(1):154-60. doi: 10.1136/annrheumdis-2012-202443. Epub 2012 Dec 21.</mixed-citation><mixed-citation xml:lang="en">Doria A, Amoura Z, Cervera R, et al. Annual direct medical cost of active systemic lupus erythematosus in five European countries. Ann Rheum Dis. 2014 Jan;73(1):154-60. doi: 10.1136/annrheumdis-2012-202443. Epub 2012 Dec 21.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Nasonov E, Soloviev S, Davidson J, et al. The prevalence and incidence of Systemic Lupus Erythematosus (SLE) in selected cities from three Commonwealth of Independent States countries (the Russian Federation, Ukraine and Kazakhstan). Lupus. 2014 Feb;23(2):213-9. doi: 10.1177/0961203313512881. Epub 2013 Nov 19.and drug discovery</mixed-citation><mixed-citation xml:lang="en">Nasonov E, Soloviev S, Davidson J, et al. The prevalence and incidence of Systemic Lupus Erythematosus (SLE) in selected cities from three Commonwealth of Independent States countries (the Russian Federation, Ukraine and Kazakhstan). Lupus. 2014 Feb;23(2):213-9. doi: 10.1177/0961203313512881. Epub 2013 Nov 19.and drug discovery</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Tan EM, Cohen AS, Fries JF. The 1982 revised criteria for the classification of systemic lupus erythrematosus. Arthritis Rheum. 1982 Nov;25(11):1271-7.</mixed-citation><mixed-citation xml:lang="en">Tan EM, Cohen AS, Fries JF. The 1982 revised criteria for the classification of systemic lupus erythrematosus. Arthritis Rheum. 1982 Nov;25(11):1271-7.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Насонова ВА. Системная красная волчанка. Москва; 1972. [Nasonova VA. Sistemnaya krasnaya volchanka [Systemic Lupus Erythematosus]. Moscow; 1972.]</mixed-citation><mixed-citation xml:lang="en">Насонова ВА. Системная красная волчанка. Москва; 1972. [Nasonova VA. Sistemnaya krasnaya volchanka [Systemic Lupus Erythematosus]. Moscow; 1972.]</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15;353(24):2550-8.</mixed-citation><mixed-citation xml:lang="en">Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15;353(24):2550-8.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996 Mar;39(3):363-9.</mixed-citation><mixed-citation xml:lang="en">Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996 Mar;39(3):363-9.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Sutton EJ, Davidson JE, Bruce IN. The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review. Semin Arthritis Rheum. 2013 Dec;43(3):352-61. doi: 10.1016/j.semarthrit.2013.05.003. Epub 2013 Jun 17.</mixed-citation><mixed-citation xml:lang="en">Sutton EJ, Davidson JE, Bruce IN. The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review. Semin Arthritis Rheum. 2013 Dec;43(3):352-61. doi: 10.1016/j.semarthrit.2013.05.003. Epub 2013 Jun 17.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Barr SG, Zonana-Nacach A, Magder LS, et al. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1999 Dec;42(12):2682-8.</mixed-citation><mixed-citation xml:lang="en">Barr SG, Zonana-Nacach A, Magder LS, et al. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1999 Dec;42(12):2682-8.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu TY, Tam LS, Lee VW, et al. The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15;61(9):1159-67. doi: 10.1002/art.24725.</mixed-citation><mixed-citation xml:lang="en">Zhu TY, Tam LS, Lee VW, et al. The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15;61(9):1159-67. doi: 10.1002/art.24725.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Huscher D, Merkesdal S, Thiele K, et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis. 2006 Sep;65(9):1175-83. Epub 2006 Mar 15.</mixed-citation><mixed-citation xml:lang="en">Huscher D, Merkesdal S, Thiele K, et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis. 2006 Sep;65(9):1175-83. Epub 2006 Mar 15.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Clarke AE, Petri M, Manzi S, et al. Tri-Nation Study Group. The systemic lupus erythematosus Tri-nation Study: absence of a link between health resource use and health outcome. Rheumatology (Oxford). 2004 Aug;43(8):1016-24. Epub 2004 Jun 1.</mixed-citation><mixed-citation xml:lang="en">Clarke AE, Petri M, Manzi S, et al. Tri-Nation Study Group. The systemic lupus erythematosus Tri-nation Study: absence of a link between health resource use and health outcome. Rheumatology (Oxford). 2004 Aug;43(8):1016-24. Epub 2004 Jun 1.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Sutcliffe N, Clarke AE, Taylor R, et al. Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2001 Jan;40(1):37-47.</mixed-citation><mixed-citation xml:lang="en">Sutcliffe N, Clarke AE, Taylor R, et al. Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2001 Jan;40(1):37-47.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Carls G, Li T, Panopalis P, et al. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. J Occup Environ Med. 2009 Jan;51(1):66-79. doi: 10.1097/JOM.0b0 13e31818a405a.</mixed-citation><mixed-citation xml:lang="en">Carls G, Li T, Panopalis P, et al. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. J Occup Environ Med. 2009 Jan;51(1):66-79. doi: 10.1097/JOM.0b0 13e31818a405a.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Panopalis P, Yazdany J, Gillis JZ, et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum. 2008 Dec 15;59(12):1788-95. doi: 10.1002/art.24063.</mixed-citation><mixed-citation xml:lang="en">Panopalis P, Yazdany J, Gillis JZ, et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum. 2008 Dec 15;59(12):1788-95. doi: 10.1002/art.24063.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Fangtham M, Petri M. 2013 update: Hopkins lupus cohort. Curr Rheumatol Rep. 2013 Sep;15(9):360. doi: 10.1007/s11926-013-0360-0.</mixed-citation><mixed-citation xml:lang="en">Fangtham M, Petri M. 2013 update: Hopkins lupus cohort. Curr Rheumatol Rep. 2013 Sep;15(9):360. doi: 10.1007/s11926-013-0360-0.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Gladman DD, IbaЦez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2): 288-91.</mixed-citation><mixed-citation xml:lang="en">Gladman DD, IbaЦez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2): 288-91.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Hanly JG, Urowitz MB, O'Keeffe AG, et al. Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum. 2013 Nov;65(11):2887-97. doi: 10.1002/art.38106.</mixed-citation><mixed-citation xml:lang="en">Hanly JG, Urowitz MB, O'Keeffe AG, et al. Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum. 2013 Nov;65(11):2887-97. doi: 10.1002/art.38106.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Ruiz-Irastorza G, Egurbide MV, Olivares N, et al. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford). 2008 Jun;47(6):920-3. doi: 10.1093/rheumatology/ken121. Epub 2008 Apr 14.</mixed-citation><mixed-citation xml:lang="en">Ruiz-Irastorza G, Egurbide MV, Olivares N, et al. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford). 2008 Jun;47(6):920-3. doi: 10.1093/rheumatology/ken121. Epub 2008 Apr 14.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Nossent J, Kiss E, Rozman B, et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus. 2010 Jul;19(8):949-56. doi: 10.1177/096 1203310366572. Epub 2010 Apr 7.</mixed-citation><mixed-citation xml:lang="en">Nossent J, Kiss E, Rozman B, et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus. 2010 Jul;19(8):949-56. doi: 10.1177/096 1203310366572. Epub 2010 Apr 7.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Parker B, Urowitz MB, Gladman DD, et al. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2013 Aug;72(8):1308-14. doi: 10.1136/annrheumdis-2012-202106. Epub 2012 Sep 3.</mixed-citation><mixed-citation xml:lang="en">Parker B, Urowitz MB, Gladman DD, et al. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2013 Aug;72(8):1308-14. doi: 10.1136/annrheumdis-2012-202106. Epub 2012 Sep 3.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
